CURRENT APPROACH TO DEVELOPMENT OF BIOSIMILAR PRODUCTS CONTAINING MONOCLONAL ANTIBODIES AS AN ACTIVE SUBSTANCE – NON-CLINICAL AND CLINICAL STUDIES OF THE FIRST RUSSIAN RITUXIMAB BI... by S. M. Alekseev, K. D. Kaplanov, R. A. Ivanov, E. V. Chernyaeva

Get full text

The work of compounding pharmacies and the possible risks of violating the exclusive rights to original medicines by A. V. Alekhin, T. N. Erivantseva, V. O. Kalyatin, R. A. Ivanov, N. A. Alekhina

Get full text

Assessment of CD4⁺ cells subpopulations with the expressing CD39 and CD73 ectonucleotidases in children with psoriasis by D. G. Kuptsova, T. V. Radigina, S. V. Petrichuk, N. N. Murashkin, A. A. Khotko, R. A. Ivanov

Get full text

Extubation in Patients with Acute Stenotic Laryngotracheitis and Ways of its Solution by M. F. Yermachenko, V. V Dolgikh, A. S. Shamburova, R. A. Ivanov, L. I. Boiko, A. Yu. Kropp

Get full text

Development of Russian market for postgenome technologies by A. N. Krivenko, T. V. Fedoronchuk, E. L. Choinzonov, R. A. Ivanov, D. V. Grishin, А. V. Lisitsa, A. L. Kaysheva

Get full text

DEVELOPMENTS OF RUSSIAN ORIGINAL BIOLOGICAL AGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY RHEUMATIC DISEASES by E. L. Nasonov, V. I. Mazurov, Yu. V. Usacheva, E. V. Chernyaeva, Ya. Yu. Ustyugov, A. B. Ulitin, R. A. Ivanov

Get full text

Characteristics of subpopulation composition of peripheral blood lymphocytes in children with different forms of congenital ichthyosis by D. G. Kuptsova, N. N. Murashkin, S. G. Makarova, R. A. Ivanov, K. O. Avetisyan, T. V. Radigina, O. V. Kurbatova, S. V. Petrichuk

Get full text

Early virologic response to сеpeginterferon alfa-2b in combination with ribavirin in treatment of patients with chronic hepatitis C by O. O. Znoyko, M. V. Maevskaya, E. A. Klimova, S. L. Maksimov, S. N. Kizhlo, N. A. Petrochenkova, F. I. Nagimova, R. A. Ivanov, Yu. N. Linkova, T. V. Chernovskaya

Get full text

Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, mult... by Т. V. Korotaeva, A. V. Samtsov, A. L. Bakulev, M. M. Kokhan, I. K. Minullin, O. A. Vylegzhanina, V. V. Dubensky, B. V. Khalilov, A. A. Khotko, O. S. Zykova, I. V. Chumachenko, A. M. Lukyanov, A. V. Artemyeva, S. I. Derbin, E. Yu. Stukalina, E. V. Chernyaeva, R. A. Ivanov

Get full text

Comparative efficacy and safety of infliximab biosimilar (BCD-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, doub... by D. E. Karateev, V. I. Mazurov, E. V. Zonova, O. B. Nesmeyanova, T. V. Plaksina, D. G. Krechikova, O. V. Reshetko, L. N. Denisov, I. G. Gordeev, T. G. Pokrovskaya, O. V. Antipova, T. V. Kropotina, T. V. Povarova, P. A. Shesternya, E. N. Ushakova, N. F. Soroka, A. M. Pristrom, A. V. Eremeeva, E. V. Chernyaeva, R. A. Ivanov, U. V. Usacheva

Get full text

COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE IN... by A. M. Lila, V. I. Mazurov, E. V. Zonova, O. B. Nesmeyanova, T. V. Plaksina, D. G. Krechikova, O. V. Reshet’ko, L. N. Denisov, I. G. Gordeev, T. G. Pokrovskaya, O. V. Antipova, T. V. Kropotina, T. V. Povarova, P. A. Shesternya, E. N. Ushakova, N. F. Soroka, E. V. Kunder, A. V. Eremeeva, E. V. Chernyaeva, R. A. Ivanov, P. S. Pukhtinskaya

Get full text

Efficacy and safety of a new original interleukin 17A inhibitor in the treatment of patients with active ankylosing spondylitis: results of a basic (BCD-085-3/AILAS) and extended (... by Sh. Erdes, V. I. Mazurov, T. V. Dubinina, I. Z. Gaydukova, S. A. Lapshina, E. V. Zonova, D. G. Krechikova, T. V. Plaksina, O. V. Reshetko, S. A. Smakotina, P. А. Shesternya, I. G. Gordeev, T. G. Makulova, T. V. Povarova, T. A. Raskina, N. F. Soroka, A. M. Pristrom, E. V. Kunder, Yu. V. Usacheva, E. Yu. Stukalina, A. V. Eremeeva, E. V. Chernyaeva, R. A. Ivanov

Get full text

THE EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR (ACELLBIA®) IN RHEUMATOID ARTHRITIS AS THE FIRST BIOLOGICAL AGENT: RESULTS OF PHASE III (ALTERRA) CLINICAL TRIAL by E. L. Nasonov, V. I. Mazurov, E. V. Zonova, L. A. Knyazeva, I. M. Marusenko, O. B. Nesmeyanova, T. V. Plaksina, Yu. S. Shapovalova, E. P. Ilivanova, D. G. Krechikova, N. A. Petrochenkova, O. V. Reshetko, L. N. Denisov, I. G. Gordeev, A. F. Davydova, N. A. Eremina, E. V. Zemerova, T. B. Ivanova, A. A. Kastanayan, T. G. Pokrovskaya, S. A. Smakotina, E. A. Smolyarchuk, A. V. Artemyeva, R. A. Ivanov, Yu. V. Usacheva, E. V. Chernyaeva

Get full text